CTNNB1 Antibodies

Structure of CTNNB1

CTNNB1 (β -catenin) is a key signal transduction protein with a molecular weight of approximately 88 kDa, and its precise molecular weight varies slightly among different species:

CTNNB1 is composed of 781 amino acids, and its molecular structure contains 12 repetitive Armadillo domains, forming a superhelical conformation to mediate protein interactions. This protein regulates its stability through the N-terminal phosphorylated degradation motif (DSGXXS). When the Wnt signal is activated, its β-TrCP recognition site is protected, thereby avoiding proteasome degradation. The central Armadillo domain of CTNNB1 has a dual function: the C-terminal region binds to E-cadherin to maintain intercellular connections, while the N-terminal region forms a complex with TCF/LEF transcription factors to initiate target gene expression. The phosphorylation status of serine at position 45 determines its cytoplasmic localization or nuclear translocation ability, a characteristic that makes it a core regulatory node in developmental biology and tumor research.

Fig. 1 Dual roles of CTNNB1/β-catenin: Molecular mechanisms from cell adhesion to Wnt signaling regulation.¹

Fig. 2 CTNNB1 mutation map analysis: A newly discovered exon 3 mutation site in craniopharyngioma. ²

Key structural properties of CTNNB1:

• Armadillo repeats the domain
• Phosphorylation regulatory region
• Dual-function combined domain
• Verified location signal
• Key phosphorylation site

Functions of CTNNB1

The core function of CTNNB1 is to coordinate intercellular connections and gene transcription regulation, while also participating in multiple pathophysiological processes:

The activity of CTNNB1 exhibits bistable characteristics: it is strictly controlled by the phosphorylation-degradation complex in rest cells, while rapid nuclear accumulation occurs when Wnt is activated. This "all or none" dynamic regulatory mode is significantly different from the gradient response characteristics of other signaling proteins.

Applications of CTNNB1 and CTNNB1 Antibody in Literature

1. Zhuang, Wenting, et al. "CTNNB1 in neurodevelopmental disorders." Frontiers in psychiatry 14 (2023): 1143328. https://doi.org/10.3389/fpsyt.2023.1143328

The article shows that the CTNNB1 gene encodes β -catenin and is a key molecule in the Wnt signaling pathway. Besides being involved in cancer, recent studies have found that its mutations can lead to neurodevelopmental disorders such as intellectual disability and autism (NDDs) by affecting mechanisms like synaptic plasticity and neurogenesis, and it may be a high-risk gene and therapeutic target for NDDs.

2. He, Juan, et al. "Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing." Molecular cancer 20.1 (2021): 168.https://doi.org/10.1186/s12943-021-01468-7

The article shows that whole-genome sequencing of craniopharyngioma (CP) reveals that 68.75% of the aminogenic type (ACP) cases have CTNNB1 mutations, which are mutually exclusive to the BRAF V600E mutation of PCP. Research has found that a novel mutation in exon 3 of CTNNB1 enhances its stability by inhibiting the ubiquitination of β -catenin, activates the Wnt pathway and promotes cell proliferation.

3. Chen, Lin, et al. "CTNNB1 alternation is a potential biomarker for immunotherapy prognosis in patients with hepatocellular carcinoma." Frontiers in Immunology 12 (2021): 759565. https://doi.org/10.3389/fimmu.2021.759565

Research has found that CTNNB1 mutation (CTnNB1-MUT) can serve as a potential negative predictive marker for immunotherapy of hepatocellular carcinoma (HCC). Patients carrying this mutation have a reduced number of activated immune cells and an activated immunosuppressive pathway in the immune microenvironment, resulting in a poor response to immune checkpoint inhibitor (ICIs) treatment and a shortened progression-free survival period.

4. Ledinek, Živa, Monika Sobočan, and Jure Knez. "The role of CTNNB1 in endometrial cancer." Disease markers 2022.1 (2022): 1442441.https://doi.org/10.1155/2022/1442441

Research has found that CTNNB1 gene mutations are highly prevalent in endometrial cancer, mainly affecting the phosphorylation site of β-catenin, leading to abnormal activation of the Wnt/β-catenin signaling pathway. Although such tumors often present with low-risk characteristics, they are associated with higher recurrence rates and lower overall survival rates, and can serve as novel prognostic markers.

5. Yang, Feng, et al. "Circ-CTNNB1 drives aerobic glycolysis and osteosarcoma progression via m6A modification through interacting with RBM15." Cell proliferation 56.1 (2023): e13344. https://doi.org/10.1111/cpr.13344

Studies have found that the circular RNA circ-CTNNB1 is highly expressed in osteosarcoma. It promotes the m6A modification of key glycolytic genes such as HK2 and GPI through interaction with RBM15, thereby driving the proliferation and metastasis of osteosarcoma cells.

Creative Biolabs: CTNNB1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality CTNNB1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom CTNNB1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our CTNNB1 antibodies, custom preparations, or technical support, contact us at email.